Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ghulam Warsi

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Multivariate Behavioral Research|February 17, 2010
A Simulation Study of Mediated Effect MeasuresDavid P Mackinnon, Ghulam Warsi, James H Dwyer
Experimental Hematology & Oncology|May 19, 2018
Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphomaPatrick B Johnston, Lauren C Pinter-Brown, Ghulam Warsi, et al.
Leukemia Research|July 10, 2010
Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromesPeter L Greenberg, Charles A Koller, Z Ioav Cabantchik, et al.
Archives of Pathology & Laboratory Medicine|December 7, 2013
Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy studyLuke P Akard, Jorge E Cortes, Maher Albitar, et al.
Diabetes/Metabolism Research and Reviews|May 8, 2002
Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetesFrancisco J Gómez-Perez, Guillermo Fanghänel-Salmón, Juan Antonio Barbosa, et al.
Therapeutic Advances in Hematology|January 3, 2017
Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinibSikander Ailawadhi, Luke P Akard, Carole B Miller, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 20, 2016
Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH StudyJorge E Cortes, Jeffrey H Lipton, Carole B Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2015
Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK StudyNoopur Raje, Robert Vescio, Charles W Montgomery, et al.
The Journal of Supportive Oncology|June 30, 2006
A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trialStephen H Rosenoff, Nashat Y Gabrail, Richard Conklin, et al.
Cancer|October 12, 2011
Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozoleAdam M Brufsky, W Graydon Harker, J Thaddeus Beck, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Multivariate Behavioral Research|February 17, 2010
A Simulation Study of Mediated Effect MeasuresDavid P Mackinnon, Ghulam Warsi, James H Dwyer
Experimental Hematology & Oncology|May 19, 2018
Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphomaPatrick B Johnston, Lauren C Pinter-Brown, Ghulam Warsi, et al.
Leukemia Research|July 10, 2010
Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromesPeter L Greenberg, Charles A Koller, Z Ioav Cabantchik, et al.
Archives of Pathology & Laboratory Medicine|December 7, 2013
Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy studyLuke P Akard, Jorge E Cortes, Maher Albitar, et al.
Diabetes/Metabolism Research and Reviews|May 8, 2002
Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetesFrancisco J Gómez-Perez, Guillermo Fanghänel-Salmón, Juan Antonio Barbosa, et al.
Therapeutic Advances in Hematology|January 3, 2017
Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinibSikander Ailawadhi, Luke P Akard, Carole B Miller, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 20, 2016
Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH StudyJorge E Cortes, Jeffrey H Lipton, Carole B Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2015
Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK StudyNoopur Raje, Robert Vescio, Charles W Montgomery, et al.
The Journal of Supportive Oncology|June 30, 2006
A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trialStephen H Rosenoff, Nashat Y Gabrail, Richard Conklin, et al.
Cancer|October 12, 2011
Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozoleAdam M Brufsky, W Graydon Harker, J Thaddeus Beck, et al.
Pageof 1